BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 31914536)

  • 1. [Expression of HMGB1 protein in breast cancer and its clinicopathological significance].
    Wang CQ; Huang BF; Wang Y; Hu GR; Wang Q; Shao JK
    Zhonghua Bing Li Xue Za Zhi; 2020 Jan; 49(1):57-61. PubMed ID: 31914536
    [No Abstract]   [Full Text] [Related]  

  • 2. High ASMA
    Amornsupak K; Jamjuntra P; Warnnissorn M; O-Charoenrat P; Sa-Nguanraksa D; Thuwajit P; Eccles SA; Thuwajit C
    Clin Breast Cancer; 2017 Oct; 17(6):441-452.e2. PubMed ID: 28533055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.
    Lee HJ; Kim A; Song IH; Park IA; Yu JH; Ahn JH; Gong G
    Pathol Int; 2016 Apr; 66(4):202-9. PubMed ID: 26922571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.
    Ladoire S; Penault-Llorca F; Senovilla L; Dalban C; Enot D; Locher C; Prada N; Poirier-Colame V; Chaba K; Arnould L; Ghiringhelli F; Fumoleau P; Spielmann M; Delaloge S; Poillot ML; Arveux P; Goubar A; Andre F; Zitvogel L; Kroemer G
    Autophagy; 2015; 11(10):1878-90. PubMed ID: 26506894
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.
    Orucevic A; Chen J; McLoughlin JM; Heidel RE; Panella T; Bell J
    Breast J; 2015; 21(2):147-54. PubMed ID: 25600504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcellular localization of HMGB1 in colorectal cancer impacts on tumor grade and survival prognosis.
    Wang CQ; Huang BF; Wang Y; Tang CH; Jin HC; Shao F; Shao JK; Wang Q; Zeng Y
    Sci Rep; 2020 Oct; 10(1):18587. PubMed ID: 33122771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer.
    Zhang Z; Wang M; Zhou L; Feng X; Cheng J; Yu Y; Gong Y; Zhu Y; Li C; Tian L; Huang Q
    J Exp Clin Cancer Res; 2015 May; 34(1):51. PubMed ID: 25986235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
    Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
    Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
    Hongo K; Kazama S; Tsuno NH; Ishihara S; Sunami E; Kitayama J; Watanabe T
    World J Surg Oncol; 2015 Jan; 13():7. PubMed ID: 25622595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis.
    Zhang QB; Jia QA; Wang H; Hu CX; Sun D; Jiang RD; Zhang ZL
    BMC Cancer; 2016 Nov; 16(1):880. PubMed ID: 27836008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Ahn JH; Gong G
    Virchows Arch; 2015 Dec; 467(6):701-709. PubMed ID: 26445971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.